Pradofloxacin
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Pradofloxacin
- DrugBank Accession Number
- DB11453
- Background
Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH. It was approved by the European Commission in April 2011 for bacterial infections in dogs and cats.
- Type
- Small Molecule
- Groups
- Vet approved
- Structure
- Weight
- Average: 396.422
Monoisotopic: 396.159768715 - Chemical Formula
- C21H21FN4O3
- Synonyms
- Pradofloxacin
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Quinolines and derivatives
- Sub Class
- Quinoline carboxylic acids
- Direct Parent
- Quinoline carboxylic acids
- Alternative Parents
- Fluoroquinolones / Aminoquinolines and derivatives / Hydroquinolones / Haloquinolines / Hydroquinolines / Pyrrolopyridines / Pyridinecarboxylic acids / Dialkylarylamines / Piperidines / Aryl fluorides show 15 more
- Substituents
- Amine / Amino acid / Amino acid or derivatives / Aminoquinoline / Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzenoid / Carbonitrile show 31 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6O0T5E048I
- CAS number
- 195532-12-8
- InChI Key
- LZLXHGFNOWILIY-APPDUMDISA-N
- InChI
- InChI=1S/C21H21FN4O3/c22-16-6-13-18(26(12-3-4-12)9-15(20(13)27)21(28)29)14(7-23)19(16)25-8-11-2-1-5-24-17(11)10-25/h6,9,11-12,17,24H,1-5,8,10H2,(H,28,29)/t11-,17+/m0/s1
- IUPAC Name
- 7-[(4aS,7aS)-octahydro-1H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
- SMILES
- [H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1C#N)C(O)=O
References
- General References
- Silley P, Stephan B, Greife HA, Pridmore A: Bactericidal properties of pradofloxacin against veterinary pathogens. Vet Microbiol. 2012 May 25;157(1-2):106-11. doi: 10.1016/j.vetmic.2011.11.027. Epub 2011 Dec 2. [Article]
- Stephan B, Greife HA, Pridmore A, Silley P: Mutant prevention concentration of pradofloxacin against Porphyromonas gingivalis. Vet Microbiol. 2007 Mar 31;121(1-2):194-5. Epub 2007 Jan 13. [Article]
- Spindel ME, Veir JK, Radecki SV, Lappin MR: Evaluation of pradofloxacin for the treatment of feline rhinitis. J Feline Med Surg. 2008 Oct;10(5):472-9. doi: 10.1016/j.jfms.2008.04.003. Epub 2008 Jul 10. [Article]
- Mueller RS, Stephan B: Pradofloxacin in the treatment of canine deep pyoderma: a multicentred, blinded, randomized parallel trial. Vet Dermatol. 2007 Jun;18(3):144-51. [Article]
- Lees P: Pharmacokinetics, pharmacodynamics and therapeutics of pradofloxacin in the dog and cat. J Vet Pharmacol Ther. 2013 Jun;36(3):209-21. doi: 10.1111/jvp.12036. Epub 2013 Feb 14. [Article]
- Restrepo C, Ihrke PJ, White SD, Spiegel IB, Affolter VK: Evaluation of the clinical efficacy of pradofloxacin tablets for the treatment of canine pyoderma. J Am Anim Hosp Assoc. 2010 Sep-Oct;46(5):301-11. [Article]
- Biswas S, Maggi RG, Papich MG, Breitschwerdt EB: Molecular mechanisms of Bartonella henselae resistance to azithromycin, pradofloxacin and enrofloxacin. J Antimicrob Chemother. 2010 Mar;65(3):581-2. doi: 10.1093/jac/dkp459. Epub 2009 Dec 18. [Article]
- Govendir M, Norris JM, Hansen T, Wigney DI, Muscatello G, Trott DJ, Malik R: Susceptibility of rapidly growing mycobacteria and Nocardia isolates from cats and dogs to pradofloxacin. Vet Microbiol. 2011 Dec 15;153(3-4):240-5. doi: 10.1016/j.vetmic.2011.06.001. Epub 2011 Jun 15. [Article]
- Dowers KL, Tasker S, Radecki SV, Lappin MR: Use of pradofloxacin to treat experimentally induced Mycoplasma hemofelis infection in cats. Am J Vet Res. 2009 Jan;70(1):105-11. doi: 10.2460/ajvr.70.1.105. [Article]
- Liu X, Lazzaroni C, Aly SA, Thungrat K, Boothe DM: In vitro selection of resistance to pradofloxacin and ciprofloxacin in canine uropathogenic Escherichia coli isolates. Vet Microbiol. 2014 Dec 5;174(3-4):514-22. doi: 10.1016/j.vetmic.2014.10.011. Epub 2014 Oct 25. [Article]
- External Links
- ChemSpider
- 7978646
- 1367269
- ChEMBL
- CHEMBL1256815
- ZINC
- ZINC000003827732
- Wikipedia
- Pradofloxacin
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0589 mg/mL ALOGPS logP 0.01 ALOGPS logP -0.49 Chemaxon logS -3.8 ALOGPS pKa (Strongest Acidic) 4.33 Chemaxon pKa (Strongest Basic) 9.49 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 96.67 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 105.48 m3·mol-1 Chemaxon Polarizability 39.7 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-002b-0009000000-c0710739363af42f0ad5 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0002-0009000000-5166d0ea05bf34852de7 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-004i-0009000000-7e66f4e039194e412f38 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0002-0009000000-101e68d6ebfac4ad31ae Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-00ls-0029000000-ec7ee94787f536e6122f Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0a6r-1239000000-9e4edafcba2491bd090b Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 190.55307 predictedDeepCCS 1.0 (2019) [M+H]+ 192.94862 predictedDeepCCS 1.0 (2019) [M+Na]+ 198.86116 predictedDeepCCS 1.0 (2019)
Drug created at February 25, 2016 18:53 / Updated at February 21, 2021 18:53